Key facts
- This page summarizes Samuel C. Blackman's Form 4 filing for Day One Biopharmaceuticals, Inc. (DAWN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 12 Dec 2024, 16:06.
Samuel C. Blackman - 10 Dec 2024 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)
- Reporting relationship
- HEAD OF R&D
- Issuer ticker
- DAWN
- Reported as of
- 10 Dec 2024
- Net transaction value
- -$399,339
- SEC form
- 4
- Accepted by SEC
- 12 Dec 2024, 16:06:23 UTC
- Prior SEC filing
- 19 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Charles N. York II, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Samuel C. Blackman filed Form 4 for Day One Biopharmaceuticals, Inc. (DAWN) on 12 Dec 2024.
Change
- Previous filing in this sequence was filed on 19 Nov 2024.
- Current net transaction value: -$399,339.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DAWN
transaction
Common Stock
Sale
- Transaction value
- $399,339
- Shares
- -30,000
- Change %
- -2.8%
- Price
- $13.31
- Shares after
- 1,034,015
- Date
- 10 Dec 2024
- Ownership
- Direct
- Footnotes
- F1, F2
DAWN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,000,000
- Date
- 10 Dec 2024
- Ownership
- See footnote
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.
Footnote F2
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.14 to $13.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
The Reporting Person is the sole manager, and has shared voting and dispositive power with his wife as members. The Reporting Person continues to report beneficial ownership of all of the Issuer's Common Stock held by the 2021 Blackman Family LLC but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest therein.